The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NeurOp, Inc.’s investigational candidate NP10679 to treat Subarachnoid hemorrhage (SAH). NeurOp is working on a subunit-specific NMDA receptor inhibitor for CNS disorders called NP10679. The neurotransmitter glutamate, the most common excitatory transmitter in the brain, activates NMDA receptors.

Source: NeurOp, Inc.

Subarachnoid hemorrhage (SAH) is bleeding into the subarachnoid space between the arachnoid membrane and the pia mater surrounding the brain. Symptoms may include a severe headache of rapid onset, vomiting, decreased level of consciousness, fever, and sometimes seizures. Twenty percent of strokes are hemorrhagic, with SAH and intracerebral hemorrhage accounting for 10 percent. SAH secondary to rupture of an intracranial aneurysm is a common problem that accounts for approximately 80% of non-traumatic SAHs, 6-8% of all strokes, and 22-25% of cerebrovascular deaths. By time trends, the SAH incidence for 2019 was 7.8 per 100,000 persons, having declined from 1980 when the incidence was 10.2 per 100,000 person-years.

• In terms of prognosis, one-third of patients are expected to survive with good recovery; one-third generally survive with a disability, and one-third are expected to die.

However, the current Subarachnoid hemorrhage (SAH) treatment market share, market uptake, attribute analysis concerning the most potential emerging therapies (SFX-01, Clazosentan, Dexmedetomidine, Ketamine, GSK2256294, etc.) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for Subarachnoid hemorrhage (SAH) treatment. The key companies in the advanced development stage are Evgen Pharma, Idorsia Pharmaceuticals Ltd., Orion Pharma, Hope Pharmaceuticals, etc.

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook report on Subarachnoid hemorrhage (SAH) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030.

Thelansis specializes in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area, including rare / ultra-rare and mainstream indication. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making

• Delivery Office:
  B-1030, C Wing Vrindavan tech village, Outer ring road
  Bangalore- 560037
  India+91(124)404-1731
  clientsupport@thelansis.com
• Sales office:
  183 Asylum Street Hartford,
  CT-06103, USA
  Contact no. +1 (302) 380-3552
  m.berg@thelansis.com